Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NASDAQ:HYPD NYSE:JATT NASDAQ:XCUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$1.56+3.7%$1.70$1.41▼$5.01$9.07M1.337,848 shs18,328 shsHYPDHyperion DeFi$6.11-0.5%$9.36$0.85▼$48.40$34.77M2.51.95 million shs240,240 shsJATTJATT Acquisition$2.07+2.0%$1.57$7.80▼$12.38$35.71MN/A41,322 shs181,331 shsXCURExicure$4.73-5.4%$6.78$1.44▼$36.00$29.88M3.8472,957 shs29,587 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-1.96%-5.36%-16.20%-14.29%-57.14%HYPDHyperion DeFi+4.42%-7.39%+13.70%+25.82%-85.77%JATTJATT Acquisition+0.50%0.00%+35.33%+72.03%-50.25%XCURExicure-2.53%-10.87%-32.43%-53.70%+182.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$1.56+3.7%$1.70$1.41▼$5.01$9.07M1.337,848 shs18,328 shsHYPDHyperion DeFi$6.11-0.5%$9.36$0.85▼$48.40$34.77M2.51.95 million shs240,240 shsJATTJATT Acquisition$2.07+2.0%$1.57$7.80▼$12.38$35.71MN/A41,322 shs181,331 shsXCURExicure$4.73-5.4%$6.78$1.44▼$36.00$29.88M3.8472,957 shs29,587 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-1.96%-5.36%-16.20%-14.29%-57.14%HYPDHyperion DeFi+4.42%-7.39%+13.70%+25.82%-85.77%JATTJATT Acquisition+0.50%0.00%+35.33%+72.03%-50.25%XCURExicure-2.53%-10.87%-32.43%-53.70%+182.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 3.00Buy$15.50896.78% UpsideHYPDHyperion DeFi 2.00Hold$2.00-67.27% DownsideJATTJATT Acquisition 0.00N/AN/AN/AXCURExicure 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest APRE, JATT, XCUR, and HYPD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$11.00(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$1.50M6.04N/AN/A$3.55 per share0.44HYPDHyperion DeFi$60K579.43N/AN/A($695.52) per share-0.01JATTJATT AcquisitionN/AN/A$0.08 per share27.08($0.53) per shareN/AXCURExicureN/AN/AN/AN/A$1.12 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.96M-$2.32N/AN/AN/A-1,645.01%-78.90%-62.67%11/6/2025 (Estimated)HYPDHyperion DeFi-$49.82M-$58.40N/AN/AN/A-62,238.41%-876.25%-181.67%N/AJATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/AXCURExicure-$9.70M-$3.88N/A∞N/AN/A-192.16%-84.30%11/12/2025 (Estimated)Latest APRE, JATT, XCUR, and HYPD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025HYPDHyperion DeFiN/A-$2.50N/A-$2.50N/AN/A8/12/2025Q2 2025APREAprea Therapeutics-$0.77-$0.53+$0.24-$0.53N/A$0.12 million8/8/2025Q2 2025XCURExicureN/A-$0.41N/A-$0.41N/AN/A6/27/2025Q1 2025XCURExicureN/A-$0.45N/A$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/AHYPDHyperion DeFiN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/AXCURExicureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A5.345.34HYPDHyperion DeFi0.200.910.91JATTJATT AcquisitionN/A0.150.15XCURExicureN/A1.891.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%HYPDHyperion DeFi25.84%JATTJATT Acquisition47.97%XCURExicure42.82%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics13.63%HYPDHyperion DeFi10.86%JATTJATT Acquisition20.00%XCURExicure3.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics75.83 million5.03 millionNo DataHYPDHyperion DeFi405.69 million5.08 millionNo DataJATTJATT Acquisition317.25 million13.80 millionNot OptionableXCURExicure506.32 million6.07 millionNot OptionableAPRE, JATT, XCUR, and HYPD HeadlinesRecent News About These CompaniesExicure Posts Wider Loss in Fiscal Q2August 8, 2025 | aol.comAExicure, Inc. Reports Second Quarter 2025 Financial Results | XCUR Stock NewsAugust 8, 2025 | gurufocus.comExicure, Inc. Reports Second Quarter 2025 Financial ResultsAugust 8, 2025 | businesswire.comExicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing RequirementsAugust 4, 2025 | businesswire.comStocks to Watch: Exicure, TTECAugust 3, 2025 | marketwatch.comExicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous TransplantAugust 1, 2025 | businesswire.comXCUR | Exicure Inc. Annual Cash Flow Statement - MarketWatchJuly 19, 2025 | marketwatch.comIs Exicure Stock (XCUR) Experiencing a Dead Cat Bounce?June 30, 2025 | msn.comExicure Shares Up After Swing to Profit in 1QJune 27, 2025 | marketwatch.comExicure, Inc. Reports First Quarter 2025 Financial ResultsJune 27, 2025 | businesswire.comExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-QMay 28, 2025 | businesswire.comWhy Exicure Inc. (XCUR) Soared on MondayApril 22, 2025 | msn.comExicure’s subsidiary, GPCR Therapeutics doses 19th patient in its phase 2 study of GPC-100 in multiple myelomaApril 16, 2025 | pharmabiz.comPExicure to initiate new clinical trial in acute myeloid leukaemia with GPC-100April 15, 2025 | pharmabiz.comPExicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple MyelomaApril 14, 2025 | businesswire.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in ...April 11, 2025 | gurufocus.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)April 11, 2025 | investing.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)April 11, 2025 | businesswire.comWednesday’s Insider Moves: Top Buys and Sells in US StocksMarch 27, 2025 | investing.comExicure, Inc. Reports Full Year 2024 Financial ResultsMarch 18, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPRE, JATT, XCUR, and HYPD Company DescriptionsAprea Therapeutics NASDAQ:APRE$1.56 +0.06 (+3.67%) As of 03:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Hyperion DeFi NASDAQ:HYPD$6.11 -0.03 (-0.49%) As of 03:30 PM EasternEyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.JATT Acquisition NYSE:JATT$2.07 +0.04 (+1.97%) As of 09/4/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Exicure NASDAQ:XCUR$4.73 -0.27 (-5.42%) As of 03:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Microsoft’s AI Push Beyond OpenAI Could Drive Next Breakout Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
